Literature DB >> 8510218

Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.

D P Burns1, C Collignon, R C Desrosiers.   

Abstract

We previously described the pattern of sequence variation in gp120 following persistent infection of rhesus monkeys with the pathogenic simian immunodeficiency virus SIVmac239 molecular clone (D.P.W. Burns and R.C. Desrosiers, J. Virol. 65:1843, 1991). Sequence changes were confined largely to five variable regions (V1 to V5), four of which correspond to human immunodeficiency virus type 1 (HIV-1) gp120 variable regions. Remarkably, 182 of 186 nucleotide substitutions that were documented in these variable regions resulted in amino acid changes. This is an extremely nonrandom pattern, which suggests selective pressure driving amino acid changes in discrete variable domains. In the present study, we investigated whether neutralizing-antibody responses are one selective force responsible at least in part for the observed pattern of sequence variation. Variant env sequences called 1-12 and 8-22 obtained 69 and 93 weeks after infection of a rhesus monkey with cloned SIVmac239 were recombined into the parental SIVmac239 genome, and variant viruses were generated by transfection of cultured cells with cloned DNA. The 1-12 and 8-22 recombinants differ from the parental SIVmac239 at 18 amino acid positions in gp120 and at 5 and 10 amino acid positions, respectively, in gp41. Sequential sera from the monkey infected with cloned SIVmac239 from which the 1-12 and 8-22 variants were isolated showed much higher neutralizing antibody titers to cloned SIVmac239 than to the cloned 1-12 and 8-22 variants. For example, at 55 weeks postinfection the neutralizing antibody titer against SIVmac239 was 640 while those to the variant viruses were 40 and less than 20. Two other rhesus monkeys infected with cloned SIVmac239 showed a similar pattern. Rhesus monkeys were also experimentally infected with the cloned variants so that the type-specific nature of the neutralizing antibody responses could be verified. Indeed, each of these monkeys showed neutralizing-antibody responses of much higher titer to the homologous variant used for infection. These experiments unambiguously demonstrate that SIV mutants resistant to serum neutralization arise during the course of persistent infection of rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510218      PMCID: PMC237779          DOI: 10.1128/JVI.67.7.4104-4113.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Cell surface changes associated with mutation of visna virus in antibody-treated cell cultures.

Authors:  M Dubois-Dalcq; O Narayan; D E Griffin
Journal:  Virology       Date:  1979-01-30       Impact factor: 3.616

2.  Antigenic shift of visna virus in persistently infected sheep.

Authors:  O Narayan; D E Griffin; J Chase
Journal:  Science       Date:  1977-07-22       Impact factor: 47.728

3.  Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies.

Authors:  G Pétursson; N Nathanson; G Georgsson; H Panitch; P A Pálsson
Journal:  Lab Invest       Date:  1976-10       Impact factor: 5.662

4.  Virus mutation during 'slow infection': temporal development and characterization of mutants of visna virus recovered from sheep.

Authors:  O Narayan; D E Griffin; J E Clements
Journal:  J Gen Virol       Date:  1978-11       Impact factor: 3.891

5.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

6.  Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.

Authors:  S P Layne; M J Merges; J L Spouge; M Dembo; P L Nara
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity.

Authors:  A Meyerhans; G Dadaglio; J P Vartanian; P Langlade-Demoyen; R Frank; B Asjö; F Plata; S Wain-Hobson
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

8.  Slow virus infection: replication and mechanisms of persistence of visna virus in sheep.

Authors:  O Narayan; D E Griffin; A M Silverstein
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Precipitation of radiolabeled antigen-antibody complexes with protein A-containing Staphylococcus aureus.

Authors:  M J Brunda; P Minden; T R Sharpton; J K McClatchy; R S Farr
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

View more
  64 in total

1.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.

Authors:  Todd M Allen; Lorenzo Mortara; Bianca R Mothé; Max Liebl; Peicheng Jing; Briana Calore; Marian Piekarczyk; Richard Ruddersdorf; David H O'Connor; X Wang; Chenxi Wang; David B Allison; John D Altman; Alessandro Sette; Ronald C Desrosiers; Gerd Sutter; David I Watkins
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

7.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.

Authors:  Todd M Allen; Peicheng Jing; Briana Calore; Helen Horton; David H O'Connor; Tomas Hanke; Marian Piekarczyk; Richard Ruddersdorf; Bianca R Mothé; Carol Emerson; Nancy Wilson; Jeffrey D Lifson; Igor M Belyakov; Jay A Berzofsky; Chenxi Wang; David B Allison; David C Montefiori; Ronald C Desrosiers; Steven Wolinsky; Kevin J Kunstman; John D Altman; Alessandro Sette; Andrew J McMichael; David I Watkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

10.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.